Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Safety and efficacy of dexmedetomidine in acutely ill adults requiring non-invasive ventilation: a systematic review and meta-analysis of randomized trials

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. Hormone Replacement Therapy and Development of New Asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Respiratory Mechanics and Outcomes in Immunocompromised Patients With ARDS: A Secondary Analysis of the EFRAIM Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Response

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  • Kimberley Lewis
  • Joshua Piticaru
  • Dipayan Chaudhuri
  • John Basmaji
  • Eddy Fan
  • Morten Hylander Møller
  • John W Devlin
  • Waleed Alhazzani
Vis graf over relationer

BACKGROUND: Although clinical studies have evaluated dexmedetomidine as a strategy to improve noninvasive ventilation (NIV) comfort and tolerance in patients with acute respiratory failure (ARF), their results have not been summarized.

RESEARCH QUESTION: Does dexmedetomidine, when compared with another sedative or placebo, reduce the risk of delirium, mortality, need for intubation and mechanical ventilation, or ICU length of stay (LOS) in adults with ARF initiated on NIV in the ICU?

STUDY DESIGN AND METHODS: We electronically searched MEDLINE, EMBASE, and the Cochrane Library from inception through July 31, 2020, for randomized clinical trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes with the corresponding 95% CIs using a random-effect model.

RESULTS: Twelve RCTs were included in our final analysis (N = 738 patients). The use of dexmedetomidine, compared with other sedation strategies or placebo, reduced the risk of intubation (RR, 0.54; 95% CI, 0.41-0.71; moderate certainty), delirium (RR, 0.34; 95% CI, 0.22-0.54; moderate certainty), and ICU LOS (MD, -2.40 days; 95% CI, -3.51 to -1.29 days; low certainty). Use of dexmedetomidine was associated with an increased risk of bradycardia (RR, 2.80; 95% CI, 1.92-4.07; moderate certainty) and hypotension (RR, 1.98; 95% CI, 1.32-2.98; moderate certainty).

INTERPRETATION: Compared with any sedation strategy or placebo, dexmedetomidine reduced the risk of delirium and the need for mechanical ventilation while increasing the risk of bradycardia and hypotension. The results are limited by imprecision, and further large RCTs are needed.

TRIAL REGISTRY: PROSPERO; No.: 175086; URL: www.crd.york.ac.uk/prospero/.

OriginalsprogEngelsk
TidsskriftChest
Vol/bind159
Udgave nummer6
Sider (fra-til)2274-2288
Antal sider15
ISSN0012-3692
DOI
StatusUdgivet - jun. 2021

ID: 61927415